Page 93 - 2022-12-中国全科医学
P. 93

·1498· http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn


               lowering drugs：the CVD-REAL 2 study［J］. J Am Coll Cardiol，  ［44］LEE T M，CHANG N C，LIN S Z. Dapagliflozin，a selective
               2018，71（23）：2628-2639. DOI：10.1016/j.jacc.2018.03.009.   SGLT2 Inhibitor，attenuated cardiac fibrosis by regulating the
           ［35］QUAN N H，LI X，ZHANG J W，et al. Substrate metabolism   macrophage polarization via STAT3 signaling in infarcted rat
               regulated by Sestrin2-mTORC1 alleviates pressure overload-induced   hearts［J］. Free Radic Biol Med，2017，104：298-310. DOI：
               cardiac hypertrophy in aged heart［J］. Redox Biol，2020，36：  10.1016/j.freeradbiomed.2017.01.035.
               101637. DOI：10.1016/j.redox.2020.101637.        ［45］YE Y M，JIA X M，BAJAJ M，et al. Dapagliflozin attenuates
                                                                       +
                                                                     +
           ［36］JAIKUMKAO  K，PROMSAN  S，THONGNAK  L，et  al.          Na /H  exchanger-1 in cardiofibroblasts via AMPK activation［J］.
               Dapagliflozin ameliorates pancreatic injury and activates kidney   Cardiovasc Drugs Ther，2018，32（6）：553-558. DOI：
               autophagy by modulating the AMPK/mTOR signaling pathway in   10.1007/s10557-018-6837-3.
               obese rats［J］. J Cell Physiol，2021，236（9）：6424-6440.   ［46］BAARTSCHEER A，SCHUMACHER C A，WÜST R C，et al.
                                                                                                         +
               DOI：10.1002/jcp.30316.                               Empagliflozin decreases myocardial cytoplasmic Na  through
                                                                                     +
                                                                                       +
           ［37］FERRANNINI  E，MARK  M，MAYOUX  E.  CV  protection     inhibition of the cardiac Na /H  exchanger in rats and rabbits［J］.
               in the EMPA-REG OUTCOME trial：a “thrifty substrate”   Diabetologia，2017，60（3）：568-573. DOI：10.1007/s00125-
               hypothesis［J］. Diabetes Care，2016，39（7）：1108-1114.   016-4134-x.
               DOI：10.2337/dc16-0330.                          ［47］UTHMAN L，BAARTSCHEER A，BLEIJLEVENS B，et al.
           ［38］SANTOS-GALLEGO C G，IBANEZ J A R，ANTONIO R S，et al.    Class effects of SGLT2 inhibitors in mouse cardiomyocytes and
                                                                                   +
                                                                                                              +
                                                                                      +
               Empagliflozin induces a myocardial metabolic shift from glucose   hearts：inhibition of Na /H  exchanger，lowering of cytosolic Na
               consumption to ketone metabolism that mitigates adverse cardiac   and vasodilation［J］. Diabetologia，2018，61（3）：722-726.
               remodeling and improves myocardial contractility［J］. J Am Coll   DOI：10.1007/s00125-017-4509-7.
               Cardiol，2018，71（11）：A674. DOI：10.1016/S0735-1097（18）  ［48］ZHOU H，HU S Y，JIN Q H，et al. Mff-dependent mitochondrial
               31215-4.                                             fission contributes to the pathogenesis of cardiac microvasculature
           ［39］SANTOS-GALLEGO C G，REQUENA-IBANEZ J A，SAN            ischemia/reperfusion injury via induction of mROS-mediated
               ANTONIO R，et al. Empagliflozin ameliorates adverse left   cardiolipin oxidation and HK2/VDAC1 disassociation-involved
               ventricular remodeling in nondiabetic heart failure by enhancing   mPTP opening［J］. J Am Heart Assoc，2017，6（3）：e005328.
               myocardial energetics［J］. J Am Coll Cardiol，2019，73（15）：  DOI：10.1161/JAHA.116.005328.
               1931-1944. DOI：10.1016/j.jacc.2019.01.056.      ［49］SAWADA N，JIANG A H，TAKIZAWA F，et al. Endothelial
           ［40］梁志山，许志盟，吉庆伟 . 钠 - 葡萄糖共转运蛋白 2 抑制剂                     PGC-1α  mediates  vascular  dysfunction  in  diabetes［J］.
               治疗心力衰竭循证证据与机制的研究进展［J］. 中国临床新                         Cell  Metab，2014，19（2）：246-258.  DOI：10.1016/j.
               医   学，2021，14（6）：554-558. DOI：10.3969/j.issn.1674-   cmet.2013.12.014.
               3806.2021.06.06.                                ［50］ZHOU H，WANG S Y，ZHU P J，et al. Empagliflozin rescues
               LIANG Z S，XU Z M，JI Q W. Research progress in evidence-  diabetic myocardial microvascular injury via AMPK-mediated
               based evidence and mechanisms of sodium-glucose cotransporter 2   inhibition of mitochondrial fission［J］. Redox Biol，2018，15：
               inhibitors in treatment of heart failure［J］. Chinese Journal of New   335-346. DOI：10.1016/j.redox.2017.12.019.
               Clinical Medicine，2021，14（6）：554-558. DOI：10.3969/j.  ［51］HANSSON  G  K，LIBBY  P.  The  immune  response  in
               issn.1674-3806.2021.06.06.                           atherosclerosis：a double-edged sword［J］. Nat Rev Immunol，
           ［41］高文君，韩明华 . 急性冠脉综合征预后的预测研究进展［J］.                       2006，6（7）：508-519. DOI：10.1038/nri1882.
               心血管病学进展，2018，39（4）：606-610. DOI：10.16806/j.     ［52］NASIRI-ANSARI Ν，DIMITRIADIS G K，AGROGIANNIS G，
               cnki.issn.1004-3934.2018.04.025.                     et al. Canagliflozin attenuates the progression of atherosclerosis and
               GAO W J，HAN M H. Progress in prediction of acute coronary   inflammation process in APOE knockout mice［J］. Cardiovasc
               syndrome［J］. Advances in Cardiovascular Diseases，2018，39（4）：  Diabetol，2018，17（1）：106. DOI：10.1186/s12933-018-
               606-610. DOI：10.16806/j.cnki.issn.1004-3934.2018.04.025.   0749-1.
           ［42］王继航，沈明志，焦阳，等 . SGLT2i 在合并糖尿病动脉粥样                ［53］MANCINI S J，BOYD D，KATWAN O J，et al. Canagliflozin
               硬化性心血管疾病中的作用研究进展［J］. 中华老年多器官疾                        inhibits interleukin-1β-stimulated cytokine and chemokine
               病杂志，2021，20（4）：300-304. DOI：10.11915/j.issn.1671-    secretion in vascular endothelial cells by AMP-activated protein
               5403.2021.04.062.                                    kinase-dependent and-independent mechanisms［J］. Sci Rep，
               WANG J H，SHEN M Z，JIAO Y，et al. Research progress in role   2018，8（1）：5276. DOI：10.1038/s41598-018-23420-4.
               of SGLT2i in atherosclerotic cardiovascular disease with diabetes   ［54］NAKATSU Y，KOKUBO H，BUMDELGER B，et al. The SGLT2
               mellitus［J］. Chinese Journal of Multiple Organ Diseases in the   inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of
               Elderly，2021，20（4）：300-304. DOI：10.11915/j.issn.1671-  inflammation-related but not lipid-metabolism-related genes and
               5403.2021.04.062.                                    suppresses atherosclerosis in diabetic ApoE KO mice［J］. Int J Mol
           ［43］KANG S A，VERMA S，HASSANABAD A F，et al. Direct effects   Sci，2017，18（8）：1704. DOI：10.3390/ijms18081704.
               of empagliflozin on extracellular matrix remodelling in human cardiac   ［55］LENG W L，OUYANG X S，LEI X T，et al. The SGLT-2 inhibitor
               myofibroblasts：novel translational clues to explain EMPA-REG   dapagliflozin has a therapeutic effect on atherosclerosis in diabetic
               OUTCOME results［J］. Can J Cardiol，2020，36（4）：543-    ApoE-/- mice［J］. Mediators Inflamm，2016，2016：6305735.
               553. DOI：10.1016/j.cjca.2019.08.033.                 DOI：10.1155/2016/6305735.
   88   89   90   91   92   93   94   95   96   97   98